Profile data is unavailable for this security.
About the company
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
- Revenue in USD (TTM)1.22m
- Net income in USD-50.85m
- Incorporated2018
- Employees5.00
- LocationOnconetix Inc201 E. Fifth Street, Suite 1900CINCINNATI 45202United StatesUSA
- Phone+1 (302) 497-7115
- Fax+1 (845) 818-3588
- Websitehttps://www.onconetix.com/
More ▼
Mergers & acquisitions
| Acquired company | ONCO:NAQ since announced | Transaction value |
|---|---|---|
| Ocuvex Therapeutics Inc | -87.18% | -- |
Data delayed at least 15 minutes, as of Feb 17 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pure Harvest Corporate Group Inc | 2.48m | -6.67m | 700.10k | 25.00 | -- | 0.3106 | -- | 0.2827 | -0.0901 | -0.0901 | 0.0383 | 0.0201 | 0.2644 | 1.46 | 40.64 | 99,070.40 | -70.96 | -- | -136.76 | -- | 33.83 | -- | -268.37 | -- | 0.5886 | -0.866 | 0.7639 | -- | 1,808.41 | -- | -459.26 | -- | -- | -- |
| Apollo Biowellness Inc | 2.23m | -2.00m | 716.90k | 6.00 | -- | -- | -- | 0.3212 | -0.0189 | -0.0189 | 0.02 | -0.0216 | 0.6255 | -- | -- | -- | -56.14 | -371.95 | -- | -- | 65.52 | 58.46 | -89.76 | -533.66 | -- | -5.26 | -- | -- | 11,413.18 | -- | -50.65 | -- | -- | -- |
| ITonis Inc | 0.00 | -1.17m | 914.05k | -- | -- | -- | -- | -- | -0.0012 | -0.0012 | 0.00 | -0.0004 | 0.00 | -- | -- | -- | -187.63 | -- | -1,169.36 | -- | -- | -- | -- | -- | -- | -0.8999 | -- | -- | -- | -- | -506.86 | -- | -- | -- |
| Vitalibis Inc | 243.57k | -3.96m | 986.42k | 0.00 | -- | -- | -- | 4.05 | -0.1103 | -0.1103 | 0.0034 | -0.0069 | 0.5201 | 0.352 | -- | -- | -844.71 | -1,100.84 | -- | -- | 51.56 | -- | -1,624.14 | -2,623.60 | 0.5512 | -2.33 | -- | -- | 490.69 | -- | -207.18 | -- | -- | -- |
| Evofem Biosciences Inc | 17.73m | -5.56m | 1.13m | 32.00 | -- | -- | -- | 0.0636 | -0.058 | -0.058 | 0.0111 | -0.5661 | 0.9392 | 2.25 | 3.61 | 553,937.50 | -28.79 | -177.41 | -- | -- | 80.05 | 69.60 | -30.66 | -602.27 | 0.0797 | -0.2439 | -- | -- | 6.28 | -- | -117.93 | -- | -38.87 | -- |
| Onconetix Inc | 1.22m | -50.85m | 1.22m | 5.00 | -- | 0.363 | -- | 0.9972 | -350.74 | -350.74 | 2.14 | 2.16 | 0.03 | 1.31 | 24.33 | 244,750.00 | -120.44 | -82.49 | -240.72 | -114.71 | 85.41 | -- | -4,015.56 | -4,434.98 | 0.0706 | -17.94 | 0.0453 | -- | 4,216.95 | -- | -57.44 | -- | 44.62 | -- |
| American Green Inc | -100.00bn | -100.00bn | 1.30m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Universe Pharmaceuticals Inc | 17.86m | -3.67m | 1.51m | 216.00 | -- | 0.0269 | -- | 0.0845 | -10.13 | -10.13 | 39.18 | 99.64 | 0.2602 | 5.88 | 1.38 | 82,679.35 | -5.35 | -5.40 | -7.08 | -7.09 | 35.28 | 43.33 | -20.56 | -9.65 | 3.90 | -17.46 | 0.1416 | -- | -22.44 | -10.27 | 57.92 | -- | 46.30 | -- |
| Procyon Corp | 4.98m | -312.97k | 1.53m | 19.00 | -- | 0.7027 | -- | 0.307 | -0.0387 | -0.0387 | 0.6138 | 0.2817 | 1.47 | 2.32 | 9.90 | 262,338.40 | -10.08 | 1.19 | -12.70 | 1.44 | 78.07 | 74.40 | -6.84 | 0.8691 | 2.41 | -- | 0.00 | -- | 6.35 | 3.53 | -367.38 | -- | 17.32 | -- |
| Stemcell Holdings Inc | 9.98m | 3.10m | 1.64m | -- | -- | -- | 0.5008 | 0.1645 | 0.00008 | 0.00008 | 0.0003 | 0.0002 | 1.12 | -- | 5.20 | -- | 34.90 | -- | 68.19 | -- | 77.19 | -- | 31.04 | -- | -- | -- | 0.00 | -- | 85.10 | -- | 71.82 | -- | -- | -- |
| Panacea Life Sciences Holdings Inc | 2.76m | -7.67m | 1.73m | 40.00 | -- | -- | -- | 0.6255 | -0.4554 | -0.4554 | 0.164 | -0.5255 | 0.1537 | 1.62 | 10.13 | 69,098.25 | -42.65 | -69.04 | -- | -225.03 | -139.49 | -181.62 | -277.51 | -505.41 | 0.0285 | -2.12 | 2.58 | -- | 46.59 | -- | 12.33 | -- | -- | -- |
Data as of Feb 17 2026. Currency figures normalised to Onconetix Inc's reporting currency: US Dollar USD
5.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| DRW Securities LLCas of 31 Dec 2025 | 39.05k | 2.51% |
| Citadel Securities LLCas of 30 Sep 2025 | 15.63k | 1.01% |
| Abante Asesores Gesti�n SGIIC SAas of 31 Dec 2025 | 14.71k | 0.95% |
| UBS Securities LLCas of 31 Dec 2025 | 9.20k | 0.59% |
| Tower Research Capital LLCas of 30 Sep 2025 | 1.57k | 0.10% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 154.00 | 0.01% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 11.00 | 0.00% |
| Danske Bank A/S (Investment Management)as of 31 Dec 2025 | 1.00 | 0.00% |
| Pacific Capital Wealth Advisors, Inc.as of 31 Dec 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
